Melissa Schepers

The N-Acylpolyamine Structure Assigned as Parawixin10 Does Not Display Positive Allosteric Modulatory Activity in EAAT1-3 Radioligand Uptake Assays, nor Does It Enhance Neuronal Survival in Mice in a Dose-Dependent and Statistically Significant Way.

Journal: ACS chemical neuroscience

Published: April 03, 2026

Autoantigen mRNA-LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 06, 2026

PAD2-mediated citrullination of MBP and early myelin destabilization in multiple sclerosis.

Journal: Journal of autoimmunity

Published: February 02, 2026

Prophylactic PDE4 and PDE4B inhibition reduce lesion size and neutrophil infiltration following ischemic stroke in male mice.

Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

Published: November 04, 2025

Liver X receptors: A therapeutic target in demyelinating disorders.

Journal: Pharmacological research

Published: May 26, 2025

EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 17, 2024

A new player in the game: identification of C1ql1 as a novel factor driving OPC differentiation.

Journal: The FEBS journal

Published: October 21, 2024

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 26, 2024

Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 28, 2024

Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice.

Journal: Cells

Published: March 13, 2024

Beta-amyloid interacts with and activates the long-form phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability.

Journal: FEBS letters

Published: January 16, 2024

Amelioration of functional and histopathological consequences after spinal cord injury through phosphodiesterase 4D (PDE4D) inhibition.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: December 15, 2023

The N-Acylpolyamine Structure Assigned as Parawixin10 Does Not Display Positive Allosteric Modulatory Activity in EAAT1-3 Radioligand Uptake Assays, nor Does It Enhance Neuronal Survival in Mice in a Dose-Dependent and Statistically Significant Way.

The N-Acylpolyamine Structure Assigned as Parawixin10 Does Not Display Positive Allosteric Modulatory Activity in EAAT1-3 Radioligand Uptake Assays, nor Does It Enhance Neuronal Survival in Mice in a Dose-Dependent and Statistically Significant Way.

Autoantigen mRNA-LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity.

Autoantigen mRNA-LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity.

PAD2-mediated citrullination of MBP and early myelin destabilization in multiple sclerosis.

PAD2-mediated citrullination of MBP and early myelin destabilization in multiple sclerosis.

Prophylactic PDE4 and PDE4B inhibition reduce lesion size and neutrophil infiltration following ischemic stroke in male mice.

Prophylactic PDE4 and PDE4B inhibition reduce lesion size and neutrophil infiltration following ischemic stroke in male mice.

Liver X receptors: A therapeutic target in demyelinating disorders.

Liver X receptors: A therapeutic target in demyelinating disorders.

EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis.

EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis.

A new player in the game: identification of C1ql1 as a novel factor driving OPC differentiation.

A new player in the game: identification of C1ql1 as a novel factor driving OPC differentiation.

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system.

Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system.

Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice.

Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice.

Beta-amyloid interacts with and activates the long-form phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability.

Beta-amyloid interacts with and activates the long-form phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability.

Amelioration of functional and histopathological consequences after spinal cord injury through phosphodiesterase 4D (PDE4D) inhibition.

Amelioration of functional and histopathological consequences after spinal cord injury through phosphodiesterase 4D (PDE4D) inhibition.

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.